SCHEMBL4773068

SCHEMBL4773068

CCOC(=O)c1cc2c(Nc3cccc(Cl)c3)ncnc2[nH]1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FBP1 P09467 2/20 0.53
EGFR P00533 10/20 0.53
MAPT P10636 4/20 0.53
LMNA P02545 3/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
POLB P06746 1/20 0.53
HPGD P15428 2/20 0.52
RXFP1 Q9HBX9 1/20 0.52
ABL1 P00519 3/20 0.51
ABL2 P42684 3/20 0.51
TTBK1 Q5TCY1 1/20 0.51
TTBK2 Q6IQ55 1/20 0.51
BRAF P15056 1/20 0.51
TNNI3K Q59H18 1/20 0.51
ALOX5 P09917 2/20 0.50
ALDH1A1 P00352 3/20 0.49
KDM4E B2RXH2 2/20 0.49
PTGES O14684 1/20 0.49
MEN1 O00255 1/20 0.47
GMNN O75496 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4764786 0.84 LMNA (0.56) FBP1EGFRMAPTLMNASMN1; SMN2
SCHEMBL7494602 0.84 LMNA (0.56) FBP1EGFRMAPTLMNASMN1; SMN2
SCHEMBL4774457 0.83 TTBK1 (0.58) EGFRMAPTABL1ABL2TTBK1
SCHEMBL4771699 0.83 BRAF (0.66) EGFRMAPTABL1ABL2TTBK1
SCHEMBL7494492 0.83 BRAF (0.57) FBP1EGFRMAPTLMNASMN1; SMN2
SCHEMBL7496028 0.82 NUDT1 (0.57) FBP1EGFRMAPTLMNASMN1; SMN2
SCHEMBL7495904 0.82 ALOX15 (0.49) FBP1EGFRABL1ABL2TTBK1
SCHEMBL7495429 0.80 TTBK1 (0.52) FBP1EGFRMAPTLMNASMN1; SMN2
SCHEMBL4766993 0.80 BRAF (0.51) FBP1EGFRBRAFTNNI3KSRC
SCHEMBL4771173 0.79 TTBK1 (0.58) EGFRMAPTABL1ABL2TTBK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0836605-B1 PYRROLOPYRIMIDINES AND PROCESSES FOR THE PREPARATION THEREOF NOVARTIS AG (CH) 2002-02-06 EP claimed
EP-0836605-A1 PYRROLOPYRIMIDINES AND PROCESSES FOR THE PREPARATION THEREOF Novartis AG (CH) 1998-04-22 EP claimed
WO-1997002266-A1 PYRROLOPYRIMIDINES AND PROCESSES FOR THE PREPARATION THEREOF NOVARTIS AG (CH) 1997-01-23 WO claimed
EP-0938486-B1 SUBSTITUTED PYRROLOPYRIMIDINES AND PROCESSES FOR THEIR PREPARATION NOVARTIS AG (CH) 2008-01-16 EP disclosed
EP-0836605-B1 PYRROLOPYRIMIDINES AND PROCESSES FOR THE PREPARATION THEREOF NOVARTIS AG (CH) 2002-02-06 EP disclosed
US-6180636-B1 USED TO INHIBIT THE TYROSINE KINASE ACTIVITY OF THE RECEPTOR FOR THE EPIDERMAL GROWTH FACTOR AND C-ERBB2 KINASE AND CAN BE USED AS ANTITUMOR AGENTS NOVARTIS AG (CH) 2001-01-30 US disclosed
US-6140332-A Pyrrolopyrimidines and processes for the preparation thereof NOVARTIS AG (CH) 2000-10-31 US disclosed
EP-0938486-A1 SUBSTITUTED PYRROLOPYRIMIDINES AND PROCESSES FOR THEIR PREPARATION Novartis AG (CH) 1999-09-01 EP disclosed
EP-0836605-A1 PYRROLOPYRIMIDINES AND PROCESSES FOR THE PREPARATION THEREOF Novartis AG (CH) 1998-04-22 EP disclosed
WO-1998007726-A1 SUBSTITUTED PYRROLOPYRIMIDINES AND PROCESSES FOR THEIR PREPARATION NOVARTIS AG (CH) 1998-02-26 WO disclosed
WO-1997002266-A1 PYRROLOPYRIMIDINES AND PROCESSES FOR THE PREPARATION THEREOF NOVARTIS AG (CH) 1997-01-23 WO disclosed